Industry News

(NewsVoir); India’s leading health app, 1mg has announced the commencement of "Jaankari Hai To Jaan Hai", an awareness campaign aimed at informing consumers of cheaper alternatives when it comes to cancer medication. The company kick started this ambitious campaign on the occasion of Youth Awareness Day organised in New Delhi by Yoddhas, a prominent NGO that helps cancer patients.

Intrexon Corporation, a leader in synthetic biology, and Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced an exclusive channel collaboration (ECC) to pursue the development and commercialisation of novel biotherapeutics for the treatment of patients with phenylketonuria (PKU), a serious and debilitating metabolic disorder.

BTG plc, an international specialist healthcare company bringing announces that Health Canada has issued a Notice of Compliance approving Varithena (polidocanol injectable foam) for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein (GSV) system, above and below the knee.

The US Food and Drug Administration (FDA) has approved Aprecia Pharmaceuticals Company's Spritam (levetiracetam) for oral use as a prescription adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalised tonic-clonic seizures in adults and children with epilepsy.

The European Commission (EC) has approved under the European Union (EU) Merger Regulation the Pfizer Inc's pending acquisition of Hospira, Inc. The Commission's decision includes Pfizer’s commitment to divest certain assets.

Taro Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Keveyis™ (dichlorphenamide) 50 mg Tablets for the treatment of primary hyperkalemic and hypokalemic periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis.^[1] Keveyis is the first medicine approved by the FDA for the treatment of primary periodic paralysis, which is estimated to affect approximately 5,000 people in the United States.^[2]

Hetero Group, one of India’s leading generic pharmaceutical companies  has recently announced the launch of its biosimilar ‘Rituximab’ under the brand name Maball in India. It will be marketed and distributed by Hetero Healthcare Limited, a group company of Hetero. Rituximab is recommended as the first-line treatment for NHL and is available in a single dose vial with two strengths – 100mg/10ml and 500mg/50ml.